Comprehensive analysis of stereotactic Radiosurgery outcomes in triple-negative breast cancer patients with brain metastases: The influence of immunotherapy and prognostic factors

• Published in: Breast (Edinburgh) Vol. 76; p. 103757
• Main Authors: Turna, Menekse, Yıldırım, Berna Akkus, Numanoglu, Çakır, Akboru, Mustafa Halil, Rzazade, Rashad, Çağlar, Hale Başak
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.08.2024; Elsevier
• Subjects: brain metastasis; Radiotherapy; Stereotactic radiosurgery; Triple negative breast cancer; Stereotactic radiosurgery; brain metastasis; Radiotherapy; Triple negative breast cancer
• ISSN: 0960-9776; 1532-3080; 1532-3080
• DOI: 10.1016/j.breast.2024.103757

Breast cancer stands as the second most common solid tumors with a propensity for brain metastasis. Among metastatic breast cancer cases, the brain metastasis incidence ranges from 10 % to 30 %, with triple-negative breast cancer (TNBC) displaying a heightened risk and poorer prognosis. SRS has emerged as an effective local treatment modality for brain metastases; however, data on its outcomes specifically in pure triple-negative subtype remain scarce. We retrospectively reviewed the electronic medical records of all brain metastasis (BM) TNBC patients treated with SRS. Patient, tumour characteristics and treatment details data were collected. This retrospective cohort study aimed to evaluate local control (LC), distant brain metastasis free survival (DBMFS), and overall survival (OS) outcomes in TNBC patients undergoing SRS for brain metastases while identifying potential prognostic factors. Forty-three patients with TNBC and brain metastases treated with SRS between January 2017 and 2023 were included. The study found rates of LC (99 % at 1 year) and DBMFS (76 % at 1 year) after SRS, with brain metastasis count (p = 0,003) and systemic treatment modality (p = 0,001) being significant predictors of DBMFS. The median OS following SRS was 19.5 months, with neurological deficit (p = 0.003) and systemic treatment modality (p = 0.019) identified as significant predictors of OS. SRS demonstrates favourable outcomes in terms of local control and distant brain metastasis-free survival in TNBC. Neurological deficit and systemic treatment significantly influence overall survival, emphasizing the importance of personalized treatment approaches and (magnetic resonance imaging) MRI surveillance based on these factors. •SRS shows good local control & DBMFS in TNBC brain metastases.•Immunotherapy enhances DBMFS vs chemotherapy in TNBC.•Neurological deficit and immunotherapy significantly influence OS.